Global Icotinib Hydrochloride Tablets Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Icotinib Hydrochloride Tablets Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Icotinib (trade name Conmana) is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is approved for use as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mutations.
Icotinib Hydrochloride Tablets report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Icotinib Hydrochloride Tablets market is projected to reach US$ 28 million in 2029, increasing from US$ 15 million in 2022, with the CAGR of 8.6% during the period of 2024 to 2029. Demand from Hospital and Drugs Store are the major drivers for the industry.
The Icotinib market is primarily driven by the demand for targeted therapies in the treatment of non-small cell lung cancer (NSCLC). Icotinib is a medication used as a tyrosine kinase inhibitor for patients with advanced NSCLC that carries EGFR mutations. The increasing prevalence of lung cancer, particularly among non-smokers and those with specific genetic mutations, contributes to market growth. Moreover, advancements in personalized medicine and the demonstrated efficacy of Icotinib in improving progression-free survival further propel adoption. However, challenges include managing the cost of targeted therapies and addressing potential drug resistance or adverse effects. Navigating patient access issues, optimizing treatment sequencing, and ensuring long-term safety are ongoing concerns. The market's success relies on continuous research in lung cancer treatment, collaborations between pharmaceutical manufacturers and oncologists, and comprehensive patient education on the benefits and potential risks of Icotinib treatment while addressing the evolving challenges associated with precision oncology and cancer treatment accessibility.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Icotinib Hydrochloride Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Bette Pharma
Segment by Type
250mg
125mg
Hospital
Drugs Store
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Icotinib Hydrochloride Tablets market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Icotinib Hydrochloride Tablets, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Icotinib Hydrochloride Tablets industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Icotinib Hydrochloride Tablets in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Icotinib Hydrochloride Tablets introduction, etc. Icotinib Hydrochloride Tablets Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Icotinib Hydrochloride Tablets market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Icotinib Hydrochloride Tablets report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Icotinib Hydrochloride Tablets market is projected to reach US$ 28 million in 2029, increasing from US$ 15 million in 2022, with the CAGR of 8.6% during the period of 2024 to 2029. Demand from Hospital and Drugs Store are the major drivers for the industry.
The Icotinib market is primarily driven by the demand for targeted therapies in the treatment of non-small cell lung cancer (NSCLC). Icotinib is a medication used as a tyrosine kinase inhibitor for patients with advanced NSCLC that carries EGFR mutations. The increasing prevalence of lung cancer, particularly among non-smokers and those with specific genetic mutations, contributes to market growth. Moreover, advancements in personalized medicine and the demonstrated efficacy of Icotinib in improving progression-free survival further propel adoption. However, challenges include managing the cost of targeted therapies and addressing potential drug resistance or adverse effects. Navigating patient access issues, optimizing treatment sequencing, and ensuring long-term safety are ongoing concerns. The market's success relies on continuous research in lung cancer treatment, collaborations between pharmaceutical manufacturers and oncologists, and comprehensive patient education on the benefits and potential risks of Icotinib treatment while addressing the evolving challenges associated with precision oncology and cancer treatment accessibility.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Icotinib Hydrochloride Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bette Pharma
Segment by Type
250mg
125mg
Segment by Application
Hospital
Drugs Store
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Icotinib Hydrochloride Tablets market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Icotinib Hydrochloride Tablets, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Icotinib Hydrochloride Tablets industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Icotinib Hydrochloride Tablets in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Icotinib Hydrochloride Tablets introduction, etc. Icotinib Hydrochloride Tablets Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Icotinib Hydrochloride Tablets market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices